In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103. Spriano F, Tarantelli C, Arribas AJ, Gaudio E, et al. Br J Haematol 2022 Dec 9. doi: 10.1111/bjh.18576.

Read + Share

Amedeo Smart

Independent Medical Education

Spriano F, Tarantelli C, Arribas AJ, Gaudio E, et al. In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103. Br J Haematol 2022 Dec 9. doi: 10.1111/bjh.18576.
PMID: 36484636